Activable Photodynamic DNA Probe with an“AND”Logic Gate for Precision Skin Cancer Therapy

Photodynamic therapy(PDT)has emerged as a promising approach for squamous cell carcinoma treatment but hindered by tumor hypoxia,acquired resistance,phototoxicity,and so on.To address these issues,we developed a smart strategy utilizing activable photosensitizers delivered by an aptamer-functionalized DNA probe(ADP).The ADP incorporated an AS1411 aptamer for tumor targeting and a linear antisense oligonucleotide(ASO)for recognition of Survivin mRNA.In the absence of the target,PDT remained quenched,thereby avoiding phototoxicity during circulation and nonselective distribution.With the aid of the aptamer,ADP achieved selective targeting of tumors.Upon internalization,ADP targeted recognized Survivin mRNA,triggering PDT activation,and releasing ASO to down-regulate Survivin expression and reverse tumor resistance.Consequently,the activable photosensitizers exhibited an“AND”logic gate,combining tumor-targeting delivery and tumor-related gene activation,thus enhancing its specificity.Additionally,the incorporation of hemin into the ADP provided catalase activity,converting tumor-abundant H_(2)O_(2) into O_(2),thereby ameliorating tumor hypoxia.The resulting functionalized G-quadruplex/hemin–DNA probe complex demonstrated targeted delivery and activation,minimized side effects,and enhanced PDT efficacy in both xenograft tumor-bearing mice and patient-derived xenograft models.This study offers a unique and promising platform for efficient and safe PDT,thus holding great potential for future clinical translation and improved cancer therapy.